Navigation Links
Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
Date:1/23/2009

ss a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward-Looking Statement

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials, including possible delays in initiating or completing the trials and safety and efficacy results; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
2. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
3. Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
4. Novavax CEO to Present at Lazard Capital Markets 5th Annual Healthcare Conference
5. Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
6. Novavax CEO to Present at Oppenheimer 19th Annual Healthcare Conference
7. Novavax CEO to Present at BIO Investor Forum 2008
8. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
9. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
10. Novavax Announces Closing of $18 Million Registered Direct Offering
11. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... 2015 , ... Drug companies increasingly are adopting a business ... in its new report that the U.S. will generate the greatest demand for ... most market demand. , BCC Research examines plant-derived drugs in its report, ...
(Date:9/2/2015)... 2, 2015 BioLight Life ... the "Company"), a firm that invests in, manages ... diagnostics, announced today that presentations highlighting its IOPtiMate™ ... delivered at the Ophthalmology Futures European Forum and ... Cataract & Refractive Surgeons ("ESCRS"), both taking place ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... efficiency of their entire waste to energy process and continue to contribute to ... Major Upgrade , Temarry’s Waste to Energy process has been operating at their ...
(Date:9/1/2015)... , Sept. 1, 2015 The American ... Intent (LOI) for its Discovery Research Grant program. LOIs ... at 12:00 noon CDT. Discovery Grants ... with the potential to change current diagnostic or treatment ... grants specifically encourage novel research at its earliest stages, ...
Breaking Biology Technology:Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2
... Fiserv Imagesoft , a division of the ... it has completed enhancement of its ExchangeGuard suite of ... security of image replacement documents (IRDs), which are paper ... , ,The new features of ExchangeGuard include the ability ...
... disease Fiserv forms banking deals on East ... scientific advisor Badger Meter partners with DCSI ... quick-dissolving oral tablets for Parkinson's disease ,MILWAUKEE ... and launched a new drug for Parkinsons disease that dissolves ...
... service Time Warner in Green Bay to add Superconnect ... Appleton firm to build mobile Air Force lab ... UW researcher jumps on earthquake study opportunity ... has announced that it will add Circuit City to ...
Cached Biology Technology:Tech Digest: what's moving in the Midwest 2Tech Digest: what's moving in the Midwest 3Tech Digest: what's moving in the Midwest 2Tech Digest: what's moving in the Midwest 3
(Date:8/24/2015)... , Aug. 24, 2015  Based on its recent ... DERMALOG with the 2015 African Biometrics Company of the Year ... achieved substantial commercial success in Africa . ... , where it has implemented one of the largest biometric ... as well as the Central Bank of Nigeria ...
(Date:8/20/2015)... , Aug. 20, 2015   Sensory, Inc ... improving the user experience and security of consumer ... today announced that its TrulySecure™ is ... software to be FIDO Certified™. The ... compliance with the FIDO UAF (Universal Authentication Framework) ...
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
Breaking Biology News(10 mins):Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... led by researchers from the Amyloidosis Center at Boston ... (BMC) demonstrates that diflunisal, a generic anti-inflammatory drug, successfully ... in patients with familial transthyretin amyloidosis (ATTR). Diflunisal is ... 40 years for arthritis and pain. This ...
... this Christmas in search of sea and sun may be ... potentially bring relief to many thousands of people suffering life-threatening ... from their shape, are unprotected and under increasing threat of ... the University of York, UK. Their loss could rob future ...
... by mountain pine beetles, which have difficulty gripping the slippery ... Colorado Boulder. The findings, published online in the journal ... about which trees to cull and which to keep in ... The current mountain pine beetle epidemic has spread across ...
Cached Biology News:Widely-used anti-inflammatory drug shows success in treatment of amyloidosis 2Cone snails are for life and not just at Christmas 2Slippery bark protects trees from pine beetle attack, according to CU-Boulder study 2
... Complete kit for stabilizing 1.5mg of ... been optimised for the stabilization of aqueous ... traditional methods such as guanidine, phenol/chloroform, silica, ... Our StabMRT Kits contain all the necessary ...
Human SEAP ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
...
... This 2800mL wide mouth PYREX Fernbach-style culture ... large surface area to volume ratio. It can ... on the bottom outside edges to achieve maximal ... is approximately 63mm I.D. and accepts cotton plugs ...
Biology Products: